Loading stock data…
BAYN.DE
€38.38-0.12 (-0.31%)
Market ClosedLast close Apr 27
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bayer Aktiengesellschaft in the Healthcare sector is trading at €38.39. The stock is currently 23% below its 52-week high of €49.78, remaining 13.5% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why BAYN.DE maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€38.38
Potential Upside
5%
Whystock Fair Value€40.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target€47.63+24.1%
Range€25.00 – €60.00
Fundamentals
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€39.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Strong income play. Yield provides a meaningful total return floor.
27.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.37%
Volume
Today's trading volume
2.17M
Recent News
How MAHA Moms Are Protesting Pesticides
Activists are rallying in D.C. to protest the Trump administration’s handling of glyphosate, the weedkiller sold as Roundup.
What Bayer's US Supreme Court case means for the thousands of Roundup lawsuits
By Diana Novak Jones April 26 (Reuters) - The U.S.
Bayer Advances $7.25 Billion Roundup Settlement Ahead of Key Supreme Court Ruling
CEO signals progress but says critical legal milestones and settlement participation will shape outcome in coming weeks
Omnicom Gears Up to Report Q1 Earnings: What's in the Cards?
OMC heads into Q1 earnings with a mixed surprise history, though strong client wins, Interpublic acquisition and technological upgrades drive projected growth.
More Banks Are Earning $100 Million Fees for Advising Big M&A Targets
Among the banks earning top dollar in the recent past were Centerview Partners, Perella Weinberg Partners Goldman Sachs and Bank of America. Advisory fees are calculated off the value of the deal, and largely paid upon completion, meaning blockbuster deals can result in blockbuster paydays. Globally, corporate deals above $10 billion had their best quarter ever in the first three months of 2026, as the Trump administration takes a more lax approach to antitrust issues and tariff-related uncertainty wanes.